Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: Implications for T-cell immunotherapy

Sandhya Sharma, Mae Woods, Naren U. Mehta, Tim Sauer, Kathan S. Parikh, Michael Schmuck-Henneresse, Huimin Zhang, Birju Mehta, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Background The wider application of T cells targeting viral tumor-antigens via their native receptors is hampered by the failure to expand potent tumor-specific T cells from patients. Here, we examine reasons for and solutions to this failure, taking as our model the preparation of Epstein-Barr virus (EBV)-specific T cells (EBVSTs) for the treatment of EBV-positive lymphoma. EBVSTs could not be manufactured from almost one-third of patients, either because they failed to expand, or they expanded, but lacked EBV specificity. We identified an underlying cause of this problem and established a clinically feasible approach to overcome it. Methods CD45RO+CD45RA- memory compartment residing antigen-specific T cells were enriched by depleting CD45RA positive (+) peripheral blood mononuclear cells (PBMCs) that include naïve T cells, among other subsets, prior to EBV antigen stimulation. We then compared the phenotype, specificity, function and T-cell receptor (TCR) Vβ repertoire of EBVSTs expanded from unfractionated whole (W)-PBMCs and CD45RA-depleted (RAD)-PBMCs on day 16. To identify the CD45RA component that inhibited EBVST outgrowth, isolated CD45RA+ subsets were added back to RAD-PBMCs followed by expansion and characterization. The in vivo potency of W-EBVSTs and RAD-EBVSTs was compared in a murine xenograft model of autologous EBV+ lymphoma. Results Depletion of CD45RA+ PBMCs before antigen stimulation increased EBVST expansion, antigen-specificity and potency in vitro and in vivo. TCR sequencing revealed a selective outgrowth in RAD-EBVSTs of clonotypes that expanded poorly in W-EBVSTs. Inhibition of antigen-stimulated T cells by CD45RA+ PBMCs could be reproduced only by the naïve T-cell fraction, while CD45RA+ regulatory T cells, natural killer cells, stem cell memory and effector memory subsets lacked inhibitory activity. Crucially, CD45RA depletion of PBMCs from patients with lymphoma enabled the outgrowth of EBVSTs that failed to expand from W-PBMCs. This enhanced specificity extended to T cells specific for other viruses. Conclusion Our findings suggest that naïve T cells inhibit the outgrowth of antigen-stimulated memory T cells, highlighting the profound effects of intra-T-cell subset interactions. Having overcome our inability to generate EBVSTs from many patients with lymphoma, we have introduced CD45RA depletion into three clinical trials: NCT01555892 and NCT04288726 using autologous and allogeneic EBVSTs to treat lymphoma and NCT04013802 using multivirus-specific T cells to treat viral infections after hematopoietic stem cell transplantation.

Original languageEnglish (US)
Article numberjitc-2022-006267
JournalJournal for immunotherapy of cancer
Volume11
Issue number4
DOIs
StatePublished - Apr 18 2023

Keywords

  • Adaptive Immunity
  • Immunotherapy
  • Immunotherapy, Adoptive
  • T-Lymphocytes
  • Humans
  • Memory T Cells
  • Leukocytes, Mononuclear
  • Receptors, Antigen, T-Cell
  • Herpesvirus 4, Human
  • Animals
  • Epstein-Barr Virus Infections/therapy
  • Lymphoma/therapy
  • Mice
  • Leukocyte Common Antigens

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Immunology and Allergy
  • Pharmacology
  • Immunology

Fingerprint

Dive into the research topics of 'Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: Implications for T-cell immunotherapy'. Together they form a unique fingerprint.

Cite this